Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Pediatr Transplant ; 25(6): e13943, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33314525

RESUMO

BACKGROUND: HHH syndrome is a rare autosomal recessive disorder of the urea cycle, caused by a deficient mitochondrial ornithine transporter. We report the first successful liver transplantation in HHH syndrome performed in a seven-year-old boy. The patient presented at 4 weeks of age with hyperammonemic coma. The plasma amino acid profile was suggestive of HHH syndrome, and the diagnosis was confirmed when sequencing of the SLC25A15 gene identified two mutations p.R275Q and p.A76D. Although immediate intervention resulted in normalization of plasma ammonia levels within 24 hours, he developed cerebral edema, coma, convulsions, and subsequent neurological sequelae. Metabolic control was difficult requiring severe protein restriction and continued treatment with sodium benzoate and L-arginine. Despite substantial developmental delay, he was referred to our center for liver transplantation because of poor metabolic control. Following cadaveric split liver transplantation, there was complete normalization of his plasma ammonia and plasma amino acid levels under a normal protein-containing diet. This excellent metabolic control was associated with a markedly improved general condition, mood and behavior, and small developmental achievements. Twelve years after liver transplantation, the patient has a stable cognitive impairment without progression of spastic diplegia. CONCLUSION: This first case of liver transplantation in HHH syndrome demonstrates that this procedure is a therapeutic option for HHH patients with difficult metabolic control.


Assuntos
Hiperamonemia/cirurgia , Transplante de Fígado , Ornitina/deficiência , Distúrbios Congênitos do Ciclo da Ureia/cirurgia , Criança , Humanos , Masculino
2.
Ann Surg ; 268(5): 876-884, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30080732

RESUMO

OBJECTIVE: To evaluate the European experience after Adult-to-adult living donor liver transplantation using the left liver (LL-aLDLT). SUMMARY BACKGROUND DATA: LL-aLDLT decreases donor risk but provides a smaller graft that increases recipient risk as compared with right liver (RL-aLDLT). However, there is little knowledge of results obtained after LL-aLDLT in Europe. METHODS: This is a European multicenter retrospective study which aims to analyze donor and recipient outcomes after 46 LL-aLDLT. RESULTS: Seventy-six percent of the grafts were harvested by minimally invasive approach. Mean donor hospital stay was 7.5 ±â€Š3.5 days. Donor liver function was minimally impaired, with 36 donors (78.3%) without any 90-day complication, and 4 (8.7%) presenting major complications. One, 3, and 5-year recipient survival was 90.9%, 82.7%, and 82.7%, respectively. However, graft survival was of 59.4%, 56.9%, and 56.9% at 1, 3, and 5 years respectively, due to a 26.1% urgent liver retransplantation (ReLT) rate, mainly due to SFSS (n = 5) and hepatic artery thrombosis (HAT, n = 5). Risk factor analysis for ReLT and HAT showed an association with a graft to body weight ratio (GBWR) <0.6% (P = 0.01 and P = 0.024, respectively) while SFSS was associated with a recipient MELD ≥14 (P = 0.019). A combination of donor age <45 years, MELD <14 and actual GBWR >0.6% was associated with a lower ReLT rate (0% vs. 33%, P = 0.044). CONCLUSIONS: Our analysis showed low donor morbidity and preserved liver function. Recipient outcomes, however, were hampered by a high ReLT rate. A strict selection of both donor and recipients is the key to minimize graft loss.


Assuntos
Transplante de Fígado/métodos , Doadores Vivos , Adulto , Europa (Continente) , Feminino , Sobrevivência de Enxerto , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento
3.
Clin Transplant ; 29(5): 425-33, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25808782

RESUMO

BACKGROUND: In patients with hepatocellular carcinoma (HCC), the outcome after liver transplantation (LT) is excellent if tumor characteristics are within the Milan criteria (MC). Expanded Asan criteria (AC) have not yet been validated in Western countries. METHODS: A total of 76 patients with HCC underwent LT. Patients were divided and compared according to Milan, UCSF, and Asan criteria. Differences between pre- and post-operative assessment were evaluated. Overall survival (OS) and disease-free survival (DFS) were compared between groups. Predictors of recurrence were investigated. RESULTS: Asan criteria provided 26% and 15% more criteria-fitting patients than MC and UCSF pre-operatively while 49% and 35% at pathological evaluation. Discrepancy between pre- and post-operative evaluation was 32% for MC, 33% for UCSF, and 18% for AC (p = 0.06). After a median follow-up of 70.5 months, patients exceeding MC but fulfilling Asan had comparable 5-yr OS and DFS to patients fulfilling MC (p = 0.17; p = 0.29). Patients exceeding UCSF but fulfilling AC had comparable 5-yr OS and DFS to patients fulfilling UCSF (p = 0.26; p = 0.32). Number of nodules, macro-vascular invasion, capsular invasion, and exceeding AC predicted recurrence at multivariate analysis (p = 0.01, 0.03, 0.01, 0.02, respectively). CONCLUSIONS: The extension to AC allows increasing the number of patients eligible for LT without affecting OS and DFS.


Assuntos
Carcinoma Hepatocelular/cirurgia , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Recidiva Local de Neoplasia/cirurgia , Complicações Pós-Operatórias , Bélgica , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/patologia , Estudos de Viabilidade , Feminino , Seguimentos , Sobrevivência de Enxerto , Humanos , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Seleção de Pacientes , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida
4.
HPB (Oxford) ; 16(1): 75-82, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23490275

RESUMO

BACKGROUND: As a consequence of continuous technical developments in liver surgery, laparoscopic liver resection (LLR) is increasingly performed worldwide. METHODS: Between January 2004 and December 2011, 265 LLR were performed in 242 patients for various diseases. The experience of LLR is reported focusing on risk factors of conversion and their management. RESULTS: The overall conversion rate was 17/265 (6.4%), equally distributed over the period of the study. Statistically significant factors for conversion were found to be LLR of the postero-superior (P-S) segments (SI, SIVa; SVII; SVIII) (12.7% converted versus 2.5% non-converted groups, P = 0.01) and a major compared with a minor hepatectomy (15.2% vs. 4.6%, P = 0.02 respectively). A R0 resection was achieved in 93.2% of cases. According to Dindo's classification, complications were recorded as grade I (n = 20); grade II (6); grade III (11) and grade IV(1) events (total morbidity rate of 14%). Univariate analysis identified a major hepatectomy and resection involving P-S segments as prognostic factors for conversion whereas multivariate analysis identified the latter as an independent risk factor [P = 0.003, odds ratio (OR) = 5.9, 95% confidence interval (CI) = 1.8-18.8]. CONCLUSIONS: LLR can be safely performed with low overall morbidity. According to this experience and irrespective of the learning curve, resections of P-S segments were identified as an independent risk factor for conversion in LLR.


Assuntos
Hepatectomia/efeitos adversos , Laparoscopia/efeitos adversos , Adulto , Idoso , Distribuição de Qui-Quadrado , Competência Clínica , Feminino , Hepatectomia/métodos , Humanos , Curva de Aprendizado , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Complicações Pós-Operatórias/etiologia , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
5.
Liver Transpl ; 17(7): 836-48, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21384528

RESUMO

The portal vein flow (PVF), portal vein pressure (PVP), and hepatic venous pressure gradient (HVPG) were prospectively assessed to explore their relationships and to better define hyperflow and portal hypertension (PHT) during liver transplantation (LT). Eighty-one LT procedures were analyzed. No correlation between PVF and PVP was observed. Increases in the central venous pressure (CVP) were transmitted to the PVP (58%, range = 25%-91%, P = 0.001). Severe PHT (HVPG ≥ 15 mm Hg) showed a significant reciprocal association with high PVF (P = 0.023) and lower graft survival (P = 0.04). According to this initial experience, an HVPG value ≥ 15 mm Hg is a promising tool for the evaluation of hemodynamic stress potentially influencing outcomes. An algorithm for graft inflow modulation based on flows, gradients, and systemic hemodynamics is provided. In conclusion, the evaluation of PHT severity with PVP could be delusive because of the influence of CVP. PVF and PVP do not correlate and should not be used individually to assess hyperflow and PHT during LT.


Assuntos
Transplante de Fígado/métodos , Pressão na Veia Porta/fisiologia , Veia Porta/patologia , Idoso , Algoritmos , Pressão Venosa Central , Feminino , Hemodinâmica , Humanos , Hipertensão Portal/fisiopatologia , Hipertensão Portal/terapia , Fígado/fisiologia , Masculino , Pessoa de Meia-Idade , Pressão , Estudos Prospectivos , Resultado do Tratamento
6.
Transpl Int ; 24(6): 619-26, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21401731

RESUMO

Haptoglobin (Hp) is a polymorphic plasma protein with multiple functions defined by three major phenotypes (Hp 1-1, Hp 2-1, and Hp 2-2). In this article, the effects of the donor Hp phenotype (determined by starch gel electrophoresis) on the outcome and the iron status after liver transplantation were investigated. A total of 450 liver transplant patients were enrolled in this study with a median follow-up of 37 months. Kaplan-Meier and Cox regression survival analyses showed a significantly worse graft survival for liver transplantation cases with an Hp 2-2 donor phenotype, which was associated with an increased mortality rate in this group. In male patients, the Hp 2-2 phenotype was associated with higher serum ferritin concentrations, which may be linked to the significantly increased likelihood of infectious complications in this phenotype. Liver transplant patients with Hp 1-1 and Hp 2-1 grafts had a better outcome probability than recipients of an Hp 2-2 graft, which may be explained by differences in iron metabolism induced by the Hp genotype of the graft.


Assuntos
Sobrevivência de Enxerto/genética , Haptoglobinas/genética , Transplante de Fígado/mortalidade , Adulto , Doença Hepática Terminal/cirurgia , Feminino , Ferritinas/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo , Polimorfismo Genético , Análise de Sobrevida , Doadores de Tecidos , Resultado do Tratamento
7.
Surg Endosc ; 25(1): 79-87, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20532569

RESUMO

BACKGROUND: Laparoscopic left lateral sectionectomy (LLS) has gained popularity in its use for benign and malignant tumors. This report describes the evolution of the authors' experience using laparoscopic LLS for different indications including living liver donation. METHODS: Between January 2004 and January 2009, 37 consecutive patients underwent laparoscopic LLS for benign, primary, and metastatic liver diseases, and for one case of living liver donation. Resection of malignant tumors was indicated for 19 (51%) of the 37 patients. RESULTS: All but three patients (deceased due to metastatic cancer disease) are alive and well after a median follow-up period of 20 months (range, 8-46 months). Liver cell adenomas (72%) were the main indication among benign tumors, and colorectal liver metastases (84%) were the first indication of malignancy. One case of live liver donation was performed. Whereas 16 patients (43%) had undergone a previous abdominal surgery, 3 patients (8%) had LLS combined with bowel resection. The median operation time was of 195 min (range, 115-300 min), and the median blood loss was of 50 ml (range, 0-500 ml). Mild to severe steatosis was noted in 7 patients (19%) and aspecific portal inflammation in 11 patients (30%). A median free margin of 5 mm (range, 5-27 mm) was achieved for all cancer patients. The overall recurrence rate for colorectal liver metastases was of 44% (7 patients), but none recurred at the surgical margin. No conversion to laparotomy was recorded, and the overall morbidity rate was 8.1% (1 grade 1 and 2 grade 2 complications). The median hospital stay was 6 days (range, 2-10 days). CONCLUSIONS: Laparoscopic LLS without portal clamping can be performed safely for cases of benign and malignant liver disease with minimal blood loss and overall morbidity, free resection margins, and a favorable outcome. As the ultimate step of the learning curve, laparoscopic LLS could be routinely proposed, potentially increasing the donor pool for living-related liver transplantation.


Assuntos
Hepatectomia/métodos , Laparoscopia/métodos , Neoplasias Hepáticas/cirurgia , Doadores Vivos , Coleta de Tecidos e Órgãos/métodos , Adenocarcinoma/secundário , Adenocarcinoma/cirurgia , Adenoma/cirurgia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Perda Sanguínea Cirúrgica , Camptotecina/administração & dosagem , Camptotecina/análogos & derivados , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/cirurgia , Terapia Combinada , Intervalo Livre de Doença , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Tumores do Estroma Gastrointestinal/secundário , Tumores do Estroma Gastrointestinal/cirurgia , Humanos , Tempo de Internação/estatística & dados numéricos , Leucovorina/administração & dosagem , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Transplante de Fígado , Masculino , Melanoma/secundário , Melanoma/cirurgia , Pessoa de Meia-Idade , Compostos Organoplatínicos/administração & dosagem , Complicações Pós-Operatórias/epidemiologia , Estudos Retrospectivos
8.
Liver Transpl ; 16(11): 1278-87, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21031543

RESUMO

New-onset diabetes after transplantation (NODAT) is a frequent complication after liver transplantation and has a negative impact on both patient and graft survival. In analogy with the previous finding of an association between posttransplant hypomagnesemia and NODAT in renal transplant recipients, the relation between both pretransplant and posttransplant hypomagnesemia and NODAT was studied in liver transplant recipients (LTRs). One hundred sixty-nine adult LTRs (>18 years old) without diabetes who underwent transplantation between 2004 and 2009 were studied (mean age = 52.11 ± 12.6 years, proportion of LTRs who were male = 67.5%, body mass index = 25.5 ± 4.4 kg/m², proportion receiving tacrolimus = 90.0%). NODAT was defined according to the American Diabetes Association criteria. The association of NODAT with both pretransplant and posttransplant serum magnesium (Mg) was examined. Overall, 52 of 169 patients (30.8%) developed NODAT, and 57.7% of these (30 patients) were treated with antidiabetic drugs. Both pretransplant Mg levels and Mg levels in the first month after transplantation were lower in patients developing NODAT (P = 0.008 and P = 0.001, respectively). A multivariate regression model (adjusted for weight, pretransplant glucose levels, hyperglycemia in the first week after transplantation, gender, hepatitis C, and corticosteroid dosing) demonstrated both pretransplant Mg levels (hazard ratio = 0.844 per 0.1 mg/dL increase, 95% confidence interval = 0.764-0.932, P = 0.001) and posttransplant Mg levels (hazard ratio = 0.659, 95% confidence interval = 0.518-0.838, P = 0.001) to be independent predictors of NODAT together with age, biopsy-proven acute rejection, and cytomegalovirus (CMV) infection in the first year after transplantation. In conclusion, pretransplant hypomagnesemia and early posttransplant hypomagnesemia are independent predictors of new-onset diabetes after liver transplantation. Other risk factors are age, biopsy-proven acute rejection, and CMV infection.


Assuntos
Diabetes Mellitus/etiologia , Hepatopatias/cirurgia , Transplante de Fígado , Magnésio/sangue , Adulto , Biomarcadores , Estudos de Casos e Controles , Infecções por Citomegalovirus/complicações , Diabetes Mellitus/fisiopatologia , Feminino , Sobrevivência de Enxerto , Humanos , Hiperglicemia/sangue , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Hepatopatias/complicações , Transplante de Fígado/efeitos adversos , Masculino , Doenças Metabólicas/etiologia , Pessoa de Meia-Idade , Análise Multivariada , Modelos de Riscos Proporcionais , Risco , Fatores de Risco , Tacrolimo/efeitos adversos , Tacrolimo/uso terapêutico , Adulto Jovem
9.
Transpl Int ; 23(6): 611-8, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20002657

RESUMO

The Belgian experience with donation after cardiac death (DCD) liver transplantation (LT) was retrospectively reviewed, particularly evaluating patient and graft survivals, and biliary complications. From 2003 to 2007, 58 DCD-LT were performed in Belgium. Mean procurement total warm ischemia time was 25 +/- 2 min (mean +/- SEM). Mean cold ischemia time was 451 +/- 18 min. Mean follow-up was 23 +/- 2.2 months. Post-transplant peak aspartate aminotransminases was 2241 +/- 338 UI/l. Patient survivals at 1 month, 1 and 3 years, were 91.3%, 83.3% and 66.9% respectively. Graft survivals at 1 month, 1 and 3 years, were 84.4%, 72.4% and 48.8% respectively. Two patients (3.4%) developed primary nonfunction. Regarding the biliary complications, seven grafts (12%) were lost because of intrahepatic cholangiopathy, and 12 other patients (20.6%) developed bile duct stenoses requiring endoscopic and/or surgical management. The rate of symptomatic ischemic biliary lesions for grafts surviving more than 3 months was 38% (19/50). Although DCD organ donors may be a source of viable liver grafts, results were inferior to those obtained with donation after brain death LT in this series. Prognostic criteria have to be developed to improve results of DCD-LT.


Assuntos
Morte , Transplante de Fígado , Adolescente , Adulto , Idoso , Bélgica/epidemiologia , Morte Encefálica , Causas de Morte , Criança , Isquemia Fria , Feminino , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto , Humanos , Transplante de Fígado/efeitos adversos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Análise de Sobrevida , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/estatística & dados numéricos , Resultado do Tratamento
10.
World J Surg ; 34(7): 1710-5, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20422186

RESUMO

BACKGROUND: With the introduction of a self-expanding, memory-containing, circular hernia patch, surgeons have been enthusiastic about its use to repair ventral hernias smaller than 3 cm in diameter. The aim of this study was to evaluate the efficiency, reliability, and safety of the device laparoscopically with respect to adequate deployment of the patch. METHODS: During 1 year all patients with small ventral hernias were treated with this memory-containing patch and were inspected by laparoscopy. Just prior to insertion of the patch, remaining adhesions on top of the peritoneum were analyzed, as was the interference of the umbilical ligament. The final position of the patch was monitored, identifying the cupping phenomenon, exposure of the polypropylene to the viscera, and the amount of tension on the straps. All patients were followed for 2 years and postoperative complications and recurrence rate were monitored. RESULTS: Twenty-eight patients were operated on for repair of a small ventral hernia with laparoscopic control. Adhesions, not digitally palpable, that interfered with adequate patch deployment were observed in more than 80% of the cases. After a median follow-up of 25 months a 14.8% recurrence rate was observed. CONCLUSIONS: The patch, consisting of both polypropylene and ePTFE, leads to unacceptable morbidity and a high rate of recurrences. By laparoscopic evaluation, these recurrences are probably based on a combination of material characteristics and unavoidable technical errors.


Assuntos
Hérnia Ventral/cirurgia , Próteses e Implantes , Adulto , Idoso , Feminino , Hérnia Umbilical/cirurgia , Humanos , Laparoscopia , Masculino , Pessoa de Meia-Idade , Medição da Dor , Desenho de Prótese , Recidiva , Telas Cirúrgicas , Técnicas de Sutura , Aderências Teciduais , Tomografia Computadorizada por Raios X
11.
Langenbecks Arch Surg ; 395(5): 557-62, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19644704

RESUMO

PURPOSE: The aim of this study was to compare the transinguinal preperitoneal technique (TIPP) using a memory ring patch versus the Lichtenstein technique in relation to acute and chronic pain, post-operative complications and recurrence rates. METHODS: During an 18-month period, all adult patients that needed treatment for a unilateral inguinal or femoral hernia were treated by the TIPP repair using the Polysoft mesh. This group was retrospectively compared with a historical cohort of patients treated by the Lichtenstein technique. Our policy concerning type of anaesthesia, post-operative pain management and visual analogue scale measurements did not change over the study period. For post-operative pain evaluation, the visual analogue scale was used (0-10) and scores were measured after 6 h, 24 h, 1 week, 1 month, 1 year and yearly thereafter. Recurrence rates were evaluated at time of clinical examinations. RESULTS: In total, 142 patients have been analysed with the TIPP technique (group I) versus 136 patients operated in the previous 2 years with a Lichtenstein repair (group II). In group I, 112 patients (78.9%) received a medium size patch of 14 x 7.5 cm and 30 patients (21.1%) had a large patch (16 x 9 cm). The mean operative time for a TIPP procedure was statistically shorter than for a Lichtenstein repair, 33 versus 44 min, respectively (p = 0.04). After 24 h, 1 week and 1 month post-surgery, there was significantly less post-operative pain observed in the TIPP group than in the Lichtenstein group. In total, four recurrences were observed in the TIPP group (2.8%), of which one laterally and three medially. In group II, seven recurrences were observed in total (5.1%), of which five were detected within 2 years of follow-up (3.7%). CONCLUSION: For surgeons performing the Lichtenstein repair but looking for modifications concerning pain relief and a quicker procedure, the TIPP approach is a feasible alternative that seems to be associated with less post-operative pain.


Assuntos
Hérnia Inguinal/cirurgia , Complicações Pós-Operatórias/prevenção & controle , Telas Cirúrgicas , Análise de Variância , Distribuição de Qui-Quadrado , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos , Medição da Dor , Dor Pós-Operatória/prevenção & controle , Recidiva , Estudos Retrospectivos , Resultado do Tratamento
12.
Cancer Invest ; 26(8): 852-9, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18853313

RESUMO

Increased expression of glucose transporters has been reported in many cancers. It is not known whether Sodium dependent GLucose Transporter 1 (SGLT1) is up-regulated in pancreatic cancer. We studied the expression of SGLT1, Bcl-2 and p53 in primary pancreatic adenocarcinomas related to survival. In primary tumors, mean SGLT1-Hscore (n = 83) was 4.24 (median 3.0, range 0.5-15.0). Patients with positive staining for Bcl-2 had higher mean SGLT1-Hscores than those without Bcl-2 expression: 5.87 vs. 3.07 (P = 0.025). No correlation was found between expression of p53 and SGLT1 (P = 0.881). On multivariate analysis TNM stage (P = 0.015) and SGLT1 (P = 0.030) showed prognostic value for disease free survival (DFS). For overall survival (OS), TNM stage (P<0.001) and chemotherapy (P = 0.048) were prognostic and SGLT1 showed a trend (P = 0.071). In a subgroup of younger patients (age < or = median, 63.9 y) who did not receive chemotherapy, SGLT1 was a very strong predictor of DFS (P = 0.005). We conclude that high SGLT1 expression (H score > median, 3.0) in pancreatic adenocarcinomas was significantly correlated with DFS and a trend was found for OS, especially in younger patients. High SGLT1 expression in primary tumors was correlated with high Bcl-2 expression, not with p53 expression. This supports our hypothesis that SGLT1 and Bcl-2 expression could serve as prognostic markers in pancreatic cancer.


Assuntos
Adenocarcinoma/química , Proteínas de Neoplasias/análise , Neoplasias Pancreáticas/química , Proteínas Proto-Oncogênicas c-bcl-2/análise , Transportador 1 de Glucose-Sódio/análise , Proteína Supressora de Tumor p53/análise , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/mortalidade , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Adenocarcinoma Mucinoso/química , Adenocarcinoma Mucinoso/tratamento farmacológico , Adenocarcinoma Mucinoso/mortalidade , Adenocarcinoma Mucinoso/patologia , Adenocarcinoma Mucinoso/cirurgia , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/uso terapêutico , Diferenciação Celular , Terapia Combinada , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/fisiologia , Pancreatectomia , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/mortalidade , Neoplasias Pancreáticas/patologia , Neoplasias Pancreáticas/cirurgia , Prognóstico , Transportador 1 de Glucose-Sódio/fisiologia , Análise de Sobrevida
13.
Clin Transplant ; 22(4): 447-55, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18318739

RESUMO

BACKGROUND: Split liver transplantation (SLT) is an established technique developed to optimize the number of available grafts. Few data are available on SLT with extended right liver grafts (eRLG) in the context of patient-oriented allocation policy. METHODS: Between July 1, 2001 and December 31, 2005, 12 whole liver graft (WLG) recipients were matched with 12 eRLG recipients according to their clinical status, indication and year of liver transplantation. RESULTS: There were no differences according to recipient Model for End-stage Liver Disease score, total serum bilirubin, creatinine levels and international normalized ratio in both groups. Fifty percent of donors in eRLG group presented 2 or more extended criteria. Liver transplantation was performed in UNOS status 1/2A in 58% of cases in both groups. Vascular and biliary complications were observed in three patients in the eRLG group. The median follow-up was 25.3 months (range 0.4-63). Early mortality (

Assuntos
Alocação de Recursos para a Atenção à Saúde , Hepatopatias/cirurgia , Transplante de Fígado , Alocação de Recursos , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Análise por Pareamento , Pessoa de Meia-Idade , Seleção de Pacientes , Resultado do Tratamento , Adulto Jovem
14.
Surg Endosc ; 22(1): 38-44, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17705077

RESUMO

BACKGROUND: Laparoscopic liver resection (LLR) has gained wide acceptance for various liver resection procedures, mainly for benign diseases. However, only small series have been reported from a few selected centers. METHODS: Between January 2001 and January 2006, a total of 629 liver resections were performed at our institution. The indication was solid benign liver tumor in 56 (8.9%) patients. LLR was performed in 20 (35.7%) cases. Data from the LLR group were compared with those from a consecutive control group undergoing open liver surgery (OS) for similar indications in a matched-pair analysis during the same period. The pairs were matched as closely as possible for age, gender, American Society of Anesthesiologists (ASA) score, indication for resection, and type and location of the lesions. The endpoint was to investigate overall morbidity and outcome. RESULTS: All patients but one are alive and well after a mean follow-up of 35 months (range 10-60 months). Conversion laparotomy was required in two out of 20 (10%) cases for uncontrolled bleeding (one requiring temporary hemodialysis). LLR was characterized by faster time to first oral intake and shorter hospital stay compared to OS (p = 0.001 and 0.008, respectively). Incisional hernias (25%) were only recorded in the OS (p = 0.047 vs. LLR). Overall morbidity was 45% in OS versus 20% in LLR (p = 0.3). CONCLUSIONS: LLR significantly reduced time to oral intake, hospital stay, and incisional hernias compared to OS. Bleeding is a major risk and should be carefully considered when resecting benign tumors. In the hands of expert surgeons, LLR may become the gold standard for the resection of benign liver tumors located in the anterior and lateral sectors and for minor hepatic resections.


Assuntos
Hepatectomia/métodos , Laparoscopia/métodos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/cirurgia , Adulto , Idoso , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Seguimentos , Humanos , Laparoscopia/efeitos adversos , Laparotomia/efeitos adversos , Laparotomia/métodos , Tempo de Internação , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/efeitos adversos , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Estadiamento de Neoplasias , Dor Pós-Operatória/fisiopatologia , Probabilidade , Estudos Retrospectivos , Medição de Risco , Estatísticas não Paramétricas , Taxa de Sobrevida , Resultado do Tratamento
15.
Clin Chim Acta ; 366(1-2): 156-62, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16253217

RESUMO

BACKGROUND: Chronic hepatitis B (HBV) and hepatitis C (HCV) patients have elevated plasma levels of soluble CD14 (sCD14). We examined whether human hepatocytes produce sCD14 in vivo, and whether HBV or HCV infections influence this chimeric production. METHODS: uPA-SCID mice were transplanted with primary human hepatocytes and some animals were subsequently infected with HBV or HCV. Plasma from these mice was analyzed for the presence of human sCD14. The liver was examined via immunohistochemistry. RESULTS: A soluble form of human CD14 could be detected in the plasma from successfully transplanted mice, while it was completely absent in non-transplanted control animals. The isoform of this human sCD14 corresponded with the most abundant isoform found in human plasma. CD14 levels in circulation were not significantly different between non-infected, HBV infected and HCV infected animals. CONCLUSIONS: Our data indicate that human hepatocytes produce sCD14 in vivo, and that liver cells might be the major source of sCD14 in normal human plasma. In addition we demonstrate that HBV and HCV infections have no direct influence on the production of sCD14 by human hepatocytes in this chimeric model.


Assuntos
Hepatite B/fisiopatologia , Hepatite C/fisiopatologia , Hepatócitos/metabolismo , Receptores de Lipopolissacarídeos/metabolismo , Animais , Western Blotting , Transplante de Células , DNA Viral/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Hepatite B/sangue , Hepatite B/metabolismo , Antígenos de Superfície da Hepatite B/sangue , Antígenos E da Hepatite B/sangue , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Hepatite C/sangue , Hepatite C/metabolismo , Hepatócitos/transplante , Humanos , Endogamia , Receptores de Lipopolissacarídeos/sangue , Masculino , Camundongos , Camundongos Endogâmicos NOD , Camundongos Endogâmicos , Camundongos SCID , Camundongos Transgênicos , Solubilidade , Transplante Heterólogo , Ativador de Plasminogênio Tipo Uroquinase/genética , Ativador de Plasminogênio Tipo Uroquinase/metabolismo
16.
Transplantation ; 80(3): 410-3, 2005 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-16082338

RESUMO

Rapid, simple, and reliable assays to monitor allogeneic responses are essential for the safe development of novel protocols of tailored immunosuppression. Herein, we describe a real-time polymerase chain reaction method based on interleukin-2 and interferon-gamma mRNA quantification upon stimulation of whole blood with allogeneic T cell-depleted peripheral blood mononuclear cells. The technique requires only small blood volumes and results can be obtained within 48 hours. Data obtained in a liver transplant patient receiving a tolerance induction protocol based on the infusion of donor-type hematopoietic stem cells suggest that this rapid whole blood mixed lymphocyte reaction assay could be valuable for the monitoring of patients undergoing solid organ or hematopoietic stem cell transplantation.


Assuntos
Citocinas/biossíntese , Leucócitos Mononucleares/citologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Linfócitos T/citologia , Transplante Homólogo/métodos , Formação de Anticorpos , Complexo CD3/biossíntese , Citometria de Fluxo , Antígenos HLA-DR , Células-Tronco Hematopoéticas/citologia , Teste de Histocompatibilidade , Humanos , Técnicas Imunológicas , Interferon gama/metabolismo , Interleucina-2/metabolismo , Transplante de Fígado , Teste de Cultura Mista de Linfócitos , Peptídeos/química , RNA Mensageiro/metabolismo , Linfócitos T/imunologia , Fatores de Tempo , Quimeras de Transplante , Tolerância ao Transplante
17.
Eur J Gastroenterol Hepatol ; 17(8): 849-56, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16003135

RESUMO

INTRODUCTION: The Model for End-Stage Liver Disease (MELD) has been found to accurately predict pre-transplant mortality and is a valuable system for ranking patients in need of liver transplantation. Its association with post-transplant outcome, however, remains unclear. MATERIALS AND METHODS: We retrospectively studied 121 adult patients who were transplanted for non-fulminant liver failure between January 1991 and December 2001. MELD scores were calculated taking variables as close as possible prior to liver transplantation. Patients were stratified into two or three groups using different cut-off values of the MELD score. RESULTS: Indications for liver transplantation were mainly alcoholic liver disease (47.1%) or hepatitis C virus (19.0%). Gender distribution was male 62% vs female 38%. Mean age was 54 years+/-10 years. Mean MELD score was 16+/-6. Follow-up time was 5.4 years (range, 1.6-12.3 years). The use of different MELD cut-off levels yielded no difference in survival at different time points. CONCLUSION: Higher MELD scores did not have a negative impact on patient and graft survival following OLT. Since MELD is good at identifying those urgently in need of liver transplantation and high MELD scores do not appear to have an influence on long-term outcome, use of MELD in liver allocation seems warranted.


Assuntos
Falência Hepática/cirurgia , Transplante de Fígado , Índice de Gravidade de Doença , Adulto , Idoso , Feminino , Hepatite C Crônica/mortalidade , Hepatite C Crônica/cirurgia , Humanos , Hepatopatias Alcoólicas/mortalidade , Hepatopatias Alcoólicas/cirurgia , Falência Hepática/etiologia , Falência Hepática/mortalidade , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Reoperação , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento
18.
World J Gastroenterol ; 11(34): 5322-6, 2005 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-16149139

RESUMO

AIM: To examine the expression of E-cadherin, beta-catenin, gamma-catenin, VEGF, and p53 in 39 patients with hepatic metastasis from colorectal cancer immunohistochemically. METHODS: The patients were divided into two groups: those (n = 16) who had no chemotherapy for at least 6 mo before the liver resections and those (n = 23) who were treated with chemotherapy before liver resections. A score from 0 to 3 was given for the number of positive cells and from 0 to 3 for the intensity of staining in these cells, in both healthy and metastatic liver parenchyma. RESULTS: No significant differences in the expression of E-cadherin, beta- and gamma-catenin, VEGF and p53, could be observed between patients who received and did not receive chemotherapy, in both normal and metastatic liver parenchyma. CONCLUSION: Despite the assumption that chemotherapy had an effect on liver metastasis, no influences were noticed immunohistochemically.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Colorretais/patologia , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Fígado/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Fígado Gorduroso/patologia , Feminino , Humanos , Fígado/patologia , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Necrose , Estudos Retrospectivos
19.
Cancer Biother Radiopharm ; 20(2): 209-14, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15869457

RESUMO

BACKGROUND: Liver transplantation has become an important curative treatment option for hepatocellular carcinoma (HCC). Criteria for transplantation are strict and, therefore, it is crucial that patients awaiting transplantation do not suffer disease progression. One of the therapeutic options to achieve disease stabilization is neoadjuvant radiolabeled lipiodol treatment. This study aimed to document the dropout rate on the waiting list, the pathological findings on the explant livers, and the long-term outcome of patients treated with radionuclide therapy while awaiting transplantation. METHODS: Patients eligible for transplantation were treated with 2.1 GBq (131)I-lipiodol or 4.1 GBq (188)Re-HDD/lipiodol by transfemoral catheterization of the hepatic arteries. Tumor necrosis was assessed in the explant livers and follow-up data, such as dropout from the waiting list, recurrence, and survival following transplantation were retrospectively documented. RESULTS: In 5 of 22 explants, necrosis exceeded 90%. Two patients died while on the waiting list (10%) and 4 of 20 transplanted patients (20%) suffered recurrent disease. The overall recurrence-free survival was 19.7 months (range, 1.75-56), with a mean follow-up of 20.1 months. CONCLUSION: Our data support the evaluation on larger patient numbers to confirm the benefit of radiolabeled lipiodol in candidates for liver transplantation who are suffering from HCC.


Assuntos
Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/terapia , Meios de Contraste/uso terapêutico , Óleo Iodado/uso terapêutico , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/terapia , Transplante de Fígado/métodos , Carcinoma Hepatocelular/radioterapia , Progressão da Doença , Intervalo Livre de Doença , Seguimentos , Humanos , Neoplasias Hepáticas/radioterapia , Necrose , Radioisótopos/uso terapêutico , Fatores de Tempo , Resultado do Tratamento
20.
Transplantation ; 75(11): 1793-9, 2003 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-12811236

RESUMO

BACKGROUND: University of Wisconsin (UW) solution (Viaspan) is currently used to preserve organs from nonheartbeating donors. Histidine-tryptophan-ketoglutarate (HTK) solution (Custodiol) is of proven efficacy in experimental pancreas preservation, but its efficacy in combined warm ischemia (WI) and cold ischemia (CI) is unknown. The viability of HTK-preserved porcine pancreatic grafts was assessed after various periods of WI and compared with grafts flushed and preserved with UW solution. METHODS: A total of 14 pigs were used: G1 (n=4, UW) and G2 (n=4, HTK) with 15-min WI and 16-hr cold storage; G3 (n=3, UW) and G4 (n=3, HTK) with 30-min WI and 16-hr cold storage. RESULTS: All animals in G1 and G2 were normoglycemic, whereas only 66% of pancreases were functioning in G3 and G4. HTK perfusion was associated with increased wet weight. Transient hyperinsulinemia was noted in all the groups on postoperative day 1 (mean range: 8.9-12.4 microU/L). Postoperative serum amylase and lipase were more pronounced in G3 and G4. However, HTK-stored grafts exhibited less evidence of biochemical pancreatitis as compared with UW-stored grafts on the first postoperative day in the group with 15-min WI. Mean K values of intravenous glucose tolerance tests on postoperative day 14 were similar in both groups. Vascular congestion was uniformly observed and was considered a typical feature of WI. CONCLUSIONS: Porcine pancreatic grafts are viable after 16-hr CI following 15-min WI in this experimental nonheartbeating donor model. HTK solution seems to provide reliable graft function in this setting and to be equivalent to UW.


Assuntos
Adenosina/farmacologia , Alopurinol/farmacologia , Glutationa/farmacologia , Sobrevivência de Enxerto/efeitos dos fármacos , Insulina/farmacologia , Soluções para Preservação de Órgãos/farmacologia , Transplante de Pâncreas , Rafinose/farmacologia , Traumatismo por Reperfusão/patologia , Amilases/sangue , Animais , Temperatura Baixa , Edema/sangue , Edema/patologia , Temperatura Alta , Hiperinsulinismo/sangue , Hiperinsulinismo/patologia , Hipoglicemia/sangue , Hipoglicemia/patologia , Lipase/sangue , Modelos Animais , Preservação de Órgãos , Pâncreas/patologia , Pâncreas/fisiologia , Traumatismo por Reperfusão/sangue , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA